stoxline Quote Chart Rank Option Currency Glossary
Merus N.V. (MRUS)
25.13  0.39 (1.58%)    12-01 16:00
Open: 24.58
High: 25.46
Volume: 864,849
Pre. Close: 24.74
Low: 24.29
Market Cap: 1,451(M)
Technical analysis
2023-12-01 4:21:28 PM
Short term     
Mid term     
Targets 6-month :  29.8 1-year :  34.8
Resists First :  25.51 Second :  29.8
Pivot price 23.93
Supports First :  21.98 Second :  19.8
MAs MA(5) :  24.33 MA(20) :  23.91
MA(100) :  23.28 MA(250) :  20.87
MACD MACD :  0.6 Signal :  0.5
%K %D K(14,3) :  73.4 D(3) :  67.8
RSI RSI(14): 62.7
52-week High :  27.7 Low :  12.43
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ MRUS ] has closed below upper band by 2.8%. Bollinger Bands are 36% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 25.48 - 25.58 25.58 - 25.69
Low: 24.03 - 24.13 24.13 - 24.25
Close: 24.93 - 25.1 25.1 - 25.3
Company Description

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Headline News

Sat, 02 Dec 2023
Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress ... - GlobeNewswire

Thu, 30 Nov 2023
Should Biotechnology Stock Merus NV (MRUS) Be in Your Portfolio Thursday? - InvestorsObserver

Sun, 26 Nov 2023
2023-11-26 | NDAQ:MRUS | Press Release | Merus NV - Stockhouse Publishing

Wed, 08 Nov 2023
Is Merus NV (MRUS) a Winner in the Healthcare Sector? - InvestorsObserver

Mon, 23 Oct 2023
Merus' Zeno Interim Data Continues to Demonstrate Robust and ... - Yahoo Finance

Sun, 15 Oct 2023
Merus Announces Business Update Conference Call - October 15 ... - BioSpace

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 58 (M)
Shares Float 42 (M)
Held by Insiders 8.3 (%)
Held by Institutions 83.8 (%)
Shares Short 6,540 (K)
Shares Short P.Month 4,650 (K)
Stock Financials
EPS -3.73
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 6.8
Profit Margin 0 %
Operating Margin -347.8 %
Return on Assets (ttm) -22.5 %
Return on Equity (ttm) -51.1 %
Qtrly Rev. Growth 67.5 %
Gross Profit (p.s.) -1.87
Sales Per Share 0.79
EBITDA (p.s.) -2.78
Qtrly Earnings Growth 0 %
Operating Cash Flow -136 (M)
Levered Free Cash Flow -79 (M)
Stock Valuations
PE Ratio -6.76
PEG Ratio 0
Price to Book value 3.69
Price to Sales 31.76
Price to Cash Flow -10.64
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android